

Global COVID-19 Clinical Platform WITH PREGNANCY MODULE – <u>CRF-P</u>


INTRODUCTION

In response to the COVID-19 pandemic, the World Health Organization (WHO) has launched a global COVID-19 anonymized clinical data platform (the "COVID-19 Data Platform") to enable State Parties to the International Health Regulations (IHR) (2005) to share with WHO anonymized clinical data related to patients with suspected or confirmed infections with SARS-CoV-2 (collectively "anonymized COVID-19 data"). The anonymized COVID-19 data received by WHO will remain the property of the contributing Entity and will be used by WHO for purposes of verification, assessment and assistance pursuant to the IHR (2005), including to inform the public health and clinical operation response in connection with the COVID-19 outbreak. To help achieve these objectives, WHO has established an independent Clinical Advisory Group to advise WHO on global reporting and analysis of the anonymized clinical COVID-19 data. State Parties and other entities are invited to contact WHO to obtain more information about how to contribute anonymized COVID-19 data, State Parties and other entities are respectfully requested to take all necessary measures to protect their respective log-in credentials and passwords to the COVID-19 Data Platform.

The anonymized COVID-19 data will be stored in the WHO COVID-19 Data Platform, which is a secured, access-limited, password protected electronic platform. WHO will (i) protect the confidentiality and prevent the unauthorized disclosure of the anonymized COVID-19 data; (ii) implement and maintain appropriate technical and organizational security measures to protect the security of the anonymized COVID-19 data and the COVID-19 Data Platform. In accordance with Article 11(4) of the IHR (2005), WHO will not make the anonymized COVID-19 data generally available to other State Parties or entities until such time as any of the conditions set forth in paragraph 2 of Article 11 are first met, and following consultation with affected countries/entities. Pursuant to that same Article 11, WHO will not make the anonymized COVID-19 data available to the public, unless and until the anonymized COVID-19 epidemic has already been made available to State Parties, and provided that other information about the COVID-19 epidemic has already become publicly available and there is a need for the dissemination of authoritative and independent information. To contribute data to the WHO COVID-19 Data Platform or to receive more information, please contact: COVID ClinPlatform@who.int

DESIGN OF THIS PREGNANCY MODULE CASE REPORT FORM (CRF-P)

The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected retrospectively if the patient data are obtained after the admission date. The data collection period is defined as the period from hospital admission to discharge, transfer, death, or continued hospitalization without possibility of continued data collection. This CRF-P should be completed for *pregnant women* or *recently pregnant women* who delivered within 21 days from onset of symptoms. If COVID symptoms started more than 21 days after the end of the pregnancy, please complete the Rapid Core CRF only.



The Pregnancy CRF has 3 sections:

Module 1: to be completed on the first day of admission to the health centre.

Module 2: to be completed daily during hospital stay for as many days as resources allow. Continue to follow-up patients who transfer between wards.

Module 3: to be completed at discharge or death.

GENERAL GUIDANCE

Participant identification numbers consist of a site code and a participant number. Please contact us at COVID_ClinPlatform@who.int, and our data management team will provide you with instructions for data entry and will assign you a 5-digit site code at that time.

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020.

Complete at discharge/death

a. DIAGNOSTIC/PATHOGEN TESTING
Chest X-ray/CT performed? Yes No Unknown If yes: infiltrates present? Yes No Unknown
Was pathogen testing done during this illness episode?
Influenza virus: Positive Negative Not done If positive, type
Coronavirus: Positive Negative Not done If positive: MERS-CoV SARS-CoV-2 Other
Other respiratory pathogen: Positive Negative Not done If positive, specify
Viral haemorrhagic fever: Positive Negative Not done If positive, specify virus
Other pathogen of public health interest detected: If yes, specify:
Falciparum malaria: Positive Negative Not done

Non-falciparum malaria:
Positive
Negative
Not done HIV:
Positive
Negative
Not done

b. COMPLICATIONS At any time during hospitalization did the patient experience:			
Shock	□Yes □No □Unknown	Bacteraemia	□Yes □No □Unknown
Seizure	□Yes □No □Unknown	Bleeding	□Yes □No □Unknown
Meningitis/encephalitis	□Yes □No □Unknown	Endocarditis	□Yes □No □Unknown
Anaemia	□Yes □No □Unknown	Myocarditis/pericarditis	□Yes □No □Unknown
Cardiac arrhythmia	□Yes □No □Unknown	Acute renal injury	□Yes □No □Unknown
Cardiac arrest	□Yes □No □Unknown	Pancreatitis	□Yes □No □Unknown
Pneumonia	□Yes □No □Unknown	Liver dysfunction	□Yes □No □Unknown
Bronchiolitis	□Yes □No □Unknown	Cardiomyopathy	□Yes □No □Unknown
Stroke: ischaemic stroke	□Yes □No □Unknown	Acute respiratory distress syndrome (ARDS)	□Yes □No □Unknown
Stroke: intracerebral hemorrhage	□Yes □No □Unknown		
Other	□Yes □No □Unknown If Yes, specify:		

c. MEDICATION W	hile hosp	italized or at discha	rge, were any of the following administered:
Oral/orogastric fluids?	□Yes	□No □Unknown	
Intravenous fluids?	□Yes	□No □Unknown	
Antiviral?	□Yes	□No □Unknown	If yes: DRibavirin DLopinavir/ritonavir DNeuraminidase
			inhibitor □Interferon alpha □Interferon beta □Other,
			specify:
Corticosteroid?	□Yes	□No □Unknown	If yes, route: □Oral □Intravenous □Inhaled
			If yes, specify agent and
			maximum daily dose:
Antibiotic?	□Yes	□No □Unknown	If yes, specify:
Antifungal agent?	□Yes	□No □Unknown	If yes, specify:
Antimalarial agent?	□Yes	□No □Unknown	If yes, specify:
Experimental agent?	□Yes	□No □Unknown	If yes, specify:
Non-steroidal anti-inflammatory (NSAID)			
			If yes, specify:
Systematic anticoagula	ation ⊡Ye	es ⊟No ⊟Unknowr	1

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020.



d. SUPPORTIVE CARE At ANY time during hospitalization, did the patient receive/undergo:
ICU or high dependency unit admission? □Yes □No □Unknown If yes, total duration:days
Date of ICU admission [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] □ N/A
Date of ICU discharge [_D_]/[_M_]/[_A_]/[_2_][_0_][_Y_][_Y_] □ In ICU at outcome □N/A
Oxygen therapy?
O₂ flow: □ 1–5 L/min □ 6–10 L/min □ 11–15 L/min □ >15 L/min Source of oxygen: □Piped □Cylinder □Concentrator
Interface: Nasal prongs HF nasal cannula Mask Mask with reservoir CPAP/NIV mask
Non-invasive ventilation? (e.g. BIPAP, CPAP) □Yes □No □Unknown If yes, total duration:days
Invasive ventilation (any)?
Prone position? Yes Unknown If yes, total duration:days
Inotropes/vasopressors?

e. OUTCOME

Outcome: Discharged alive Despitalized Dransfer to other facility Death Dealliative discharge Duknown **Outcome date:** [D][D]/[M][M][2][0][Y][Y] DUknown

If discharged alive, ability to self-care at discharge versus before illness:
Same as before illness:
Better:
Unknown

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020.



Sections f-i (to be completed if delivery happened within 21 days of symptom onset)

f. DELIVERY, PREGNA	ANCY AND MATERNAL OUTCOMES			
Delivery during admission	□Yes □No			
Delivery date				
Mode of delivery	□ Vaginal delivery □ Caesarean section			
Onset of labour Fetal presentation at delivery	 □ Spontaneous □ Induced □ Cesarean section before labour □ Unknown □ Cephalic □ Transverse □ Breech 			
Amniotic fluid at delivery	□ Clear □ Meconium stained □ Unkno	own		
Other maternal outcomes/pregnancy complications	Gestational diabetes Gestational hypertension Anaemia (Hb < 11 g/dL) Hyperemesis Intrauterine growth restriction Placental previa/accreta/percreta Bacterial infection prior to hospital visit Pre-eclampsia/eclampsia Placental abruption Preterm contractions Preterm labour Preterm rupture of membranes Early or midterm miscarriage	□Yes □Yes □Yes □Yes □Yes □Yes □Yes □Yes	 No 	□Unknown □Unknown □Unknown □Unknown □Unknown □Unknown □Unknown □Unknown □Unknown □Unknown
	Haemorrhage If haemorrhage, which type: Embolic disease	□Yes □No □Unknown □ Antepartum/intrapartum □ □ Postpartum haemorrhage □ □ Abortion-related □Unknown		oartum orrhage
	Anesthetic complication	□Yes	□No	□Unknown

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020.

g. PREGNANCY STATUS AT DISCHARGE		
Pregnancy outcome	□Undelivered	
	□Spontaneous abortion	
	□Induced abortion	
	□Missed abortion	
	□Macerated stillbirth	
	□Fresh stillbirth	
	□Livebirth	
	□Post-abortion/postpartum on admission	
Maternal death	□Yes □No	
16	□Abortive outcome	
If yes, what was the underlying cause of death?	□Hypertensive disorders in pregnancy, childbirth and the puerperium	
	□Obstetric haemorrhage	
	□Pregnancy-related infection	
	□Other obstetric complication not included in above causes	
	□Unanticipated complications of management (e.g. anaesthesia-related complications)	
	□Indirect maternal death	
	□Obstetric death of unspecified cause	
	□Deaths from a coincidental cause (e.g. motor vehicle accident)	

h. SAMPLE COLLECTION				
Any	□Amniotic fluid	_test description	_date of collection	result
sampling	□Placenta	_test description	_date of collection	result
conducted? If so, please	□Cord blood	_test description	_date of collection]	result
describe the	□Vaginal swab	_test description]	[_date of collection]	result
test and the results	□Faeces/rectal swab	_test description]	_date of collection]	[result]
	□Pregnancy tissue in the case of fetal demise/induced abortion	[_test description]	_date of collection_]	[result]
	□Breastmilk	_test description	_date of collection	result

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020.

i. NEONATAL OUTCOMES	
Date of birth [DD/MM/YYYY]	
Time of birth [e.g. 14:21]	
Participant ID of the mother:	
	[Single digit Baby ID_]* *Complete one form per neonate
COVID-19 lab test of foetus or	Performed DNot performed DUnknown
neonate	If yes: [_sample collected_] [_test description_][_date of collection] [result]
Apgar score at 5 minutes	Score: [][]
Gestational age	Weeks: [][] Days: []
Birth weight	Grams: [][][]
Respiratory distress syndrome	□Yes □No □Unknown

Neonatal outcome	□Discharged healthy
	Discharged with complications/sequelae
	Details: []
	Clinical referral to specialist ward /other hospital
	Details: []
	\Box Death Date of death: [D][D]/[M][M]/[Y][Y]

If neonate died, primary cause of	□Preterm/low birth weight
death	□Birth asphyxia
	□Infection
	□Birth trauma
	□Congenital/birth defects
	□Other
	□Unknown
Any congenital anomalies	□Neural tube defects
	□Microcephaly
	□Congenital malformations of ear
	□Congenital heart defects
	□Orofacial clefts
	□Congenital malformations of digestive system
	□Congenital malformations of genital organs
	□Abdominal wall defects
	□Chromosomal abnormalities
	□Reduction defects of upper and lower limbs
	□Talipes equinovarus/clubfoot

This module contains section 3 (pages 9-13) from the full document "WHO Global COVID-19 Clinical Platform: Pregnancy Case Report Form"

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020.